System and method for magnifying a humoral immune response

• US 20060182742A1
• Filed: 01/28/2005
• Published: 08/17/2006
• Est. Priority Date: 08/24/2004
• Status: Abandoned Application

• Current Assignee: Deep Science LLC (Intellectual Ventures LLC)
• Original Assignee: Deep Science LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Myhrvold, Nathan P., Wood, Lowell L. Jr., Jung, Edward K.Y., Wilson, Richa
• Application Number:
  US11/046,658
• Publication Number:
  US 20060182742A1
• Time in Patent Office: Days
• US Class Current: 424/133.100
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53

Abstract

The present application relates, in general, to a system and/or method for detection and/or treatment.

Claims

1. A method, comprising:

delivering a treatment to a host wherein the treatment is associated with modulating a predicted pattern of progression of one or more computable epitopes.

2. The method of claim 1, wherein the treatment further comprises:

delivering a treatment of at least a part of one or more of a macrophage, a neutrophil, a cytotoxic cell, a lymphocyte, a T-lymphocyte, a killer T-lymphocyte, an immune response modulator, a helper T-lymphocyte, an antigen receptor, an antigen-presenting cell, a dendritic cell, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a cluster differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

3. The method of claim 1, wherein the treatment further comprises:

delivering a treatment of one or more modulators of at least a part of at least one of a macrophage, a neutrophil, a cytotoxic cell, a lymphocyte, a T-lymphocyte, a killer T-lymphocyte, an immune response modulator, a helper T-lymphocyte, an antigen receptor, an antigen-presenting cell, a dendritic cell, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a cluster differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

4. The method of claim 1, wherein the treatment further comprises:

delivering a treatment of at least a part of a B-lymphocyte.

5. The method of claim 1, wherein the treatment further comprises:

delivering a treatment of at least one modulator of at least a part of a B-lymphocyte.

6. The method of claim 1, wherein the treatment further comprises:

delivering a treatment of at least a part of at least one of an antibody, a recombinant antibody, a genetically engineered antibody, a chimeric antibody, a monospecific antibody, a bispecific antibody, a multispecific antibody, a diabody, a humanized antibody, a human antibody, a heteroantibody, a monoclonal antibody, a polyclonal antibody, a camelized antibody, a deimmunized antibody, an anti-idiotypic antibody, or an antibody fragment.

7. The method of claim 1, wherein the treatment further comprises:

delivering a treatment of one or more modulators of at least a part of at least one of an antibody, a recombinant antibody, a genetically engineered antibody, a chimeric antibody, a monospecific antibody, a bispecific antibody, a multispecific antibody, a diabody, a humanized antibody, a human antibody, a heteroantibody, a monoclonal antibody, a polyclonal antibody, a camelized antibody, a deimmunized antibody, an anti-idiotypic antibody, or an antibody fragment.

8. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering the treatment by at least one of a sub-cutaneous route, a nasal route, an intranasal route, an intramuscular route, an intravenous route, an intraarterial route, an intrathecal route, an intracapsular route, an intraorbital route, an intracardiac route, a transdermal route, a subdermal route, an intradermal route, an intraperitoneal route, a transtracheal route, a subcuticular route, an intraarticular route, a subcapsular route, a subarachnoidal route, an intraspinal route, an epidural route, an intrasternal route, an infusion route, a topical route, a sublingual route, or an enteric route.

9. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a part of at least one of a synthetic antibody or a modulator of a synthetic antibody.

10. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a part of a Fab region.

11. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a part of a Fab′

region.

12. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a part of a Fv region.

13. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a F(ab′

).sub.2 fragment.

14. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a paratope.

15. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a portion of an antibody operable for activating at least part of a complement.

16. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment of at least a portion of an antibody operable for mediating an antibody-dependent cellular cytotoxicity.

17. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment including at least a portion of a species-dependent antibody or a species-specific antibody.

18. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment directed to an extracellular molecule.

19. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment directed to at least one of a cell-surface molecule or a cell-associated molecule.

20. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment directed to at least one of a secreted protein, a polypeptide, a glycoprotein, a receptor, and/or a receptor-ligand.

21. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment for binding at least a part of at least one antibody.

22. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent.

23. The method of claim 22, wherein the delivering a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent includes:

at least one suppressor of mutational alteration of the at least one agent.

24. The method of claim 22, wherein the delivering a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent includes:

at least one interfering nucleic acid or nucleic acid sequence.

25. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering a treatment associated with modulating at least one meta-signature.

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. (canceled)

31. (canceled)

32. (canceled)

33. (canceled)

34. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. (canceled)

39. (canceled)

40. (canceled)

41. (canceled)

42. (canceled)

43. (canceled)

44. (canceled)

45. (canceled)

46. (canceled)

47. (canceled)

48. (canceled)

49. (canceled)

50. (canceled)

51. A system, comprising:

a computer readable medium including, but not limited to, a computer program for use with a computer system and wherein the computer program includes a plurality of instructions including;

one or more instructions for selecting one or more computable epitopes;

one or more instructions for predicting at least one pattern change in the one or more computable epitopes;

one or more instructions for associating the at least one pattern change in the one or more computable epitopes with at least one outcome; and

one or more instructions for designating a course of action associated with the at least one pattern change in the one or more computable epitopes.

52. (canceled)

53. (canceled)

54. (canceled)

55. (canceled)

56. A system, comprising:

circuitry for selecting one or more computable epitopes;

circuitry for predicting at least one pattern change in the one or more computable epitopes;

circuitry for associating the at least one pattern change in the one or more computable epitopes with at least one outcome; and

circuitry for designating a course of action associated with the at least one pattern change in the one or more computable epitopes.

57. A system, comprising:

means for selecting one or more computable epitopes;

means for predicting at least one pattern change in the one or more computable epitopes;

means for associating the at least one pattern change in the one or more computable epitopes with at least one outcome; and

means for designating a course of action associated with the at least one pattern change in the one or more computable epitopes.